Cancer
Anti-angiogenic tyrosine kinase inhibitors (sunitinib, sorafenib, pazopanib)
Small molecules that block the receptors through which tumours recruit new blood vessels; used in advanced renal cell carcinoma.
Mechanism of action
- Primary and metastatic solid tumours need a blood supply to grow; vascular endothelial growth factor (VEGF) is one of the most important signals for new vessels.
- These drugs inhibit several receptor tyrosine kinases inside the cell, including the VEGF receptors and the PDGF receptor.
- Blocking these signals inhibits angiogenesis, invasion and metastasis.
- Sunitinib also inhibits c-kit; sorafenib also inhibits raf kinase.
Molecular targets
- VEGF receptors (VEGF-R1, R2, R3): Tyrosine kinase inhibited
- PDGF receptors: Tyrosine kinase inhibited
Drugs in Anti-angiogenic tyrosine kinase inhibitors (sunitinib, sorafenib, pazopanib)
- Sunitinib (Also inhibits c-kit.)
- Sorafenib (Also inhibits raf kinase.)
- Pazopanib
Therapeutic uses
- Advanced renal cell carcinoma (sunitinib; sorafenib)
- Gastrointestinal stromal tumour after imatinib has failed or is not tolerated (sunitinib)
- Advanced hepatocellular carcinoma (sorafenib)
Diseases it treats
Adverse effects
- Thyroid dysfunction: these kinase inhibitors can cause hypothyroidism and alter thyroid hormone metabolism
Contraindications by condition
- Uncontrolled hypertension (Use with care): Blocking VEGF signalling raises blood pressure.
- Recent surgery, wounds or bleeding (Use with care): They impair wound healing and raise the risk of bleeding.
- Heart failure (Use with care): Sunitinib can reduce the left ventricular ejection fraction.
- Pregnancy (Contraindicated): Blocking blood vessel growth harms the fetus.
Other cautions and interactions
- Sunitinib is metabolised by CYP3A4: drugs that inhibit or induce this enzyme change its levels.
Connected topics
Written from
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 54, Cancer Chemotherapy, Bevacizumab, ziv-aflibercept, ramucirumab, sorafenib, sunitinib and pazopanib
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 38, Thyroid & Antithyroid Drugs, Drug effects on thyroid function
Educational reference. Not medical advice, diagnosis or treatment.